EXEL Exelixis, Inc.

19.35
-0.22  -1%
Previous Close 19.57
Open 19.55
Price To book 47.73
Market Cap 5.66B
Shares 292,512,000
Volume 2,378,096
Short Ratio 4.06
Av. Daily Volume 3,823,890

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment completed 1Q 2017.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
Phase 3 planned later in 2017.
CABOMETYX (cabozantinib) with Opdivo (nivolumab)
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 initiated September 2016.
CS-3150
Essential hypertension
Phase 2 top-line data released May 2016. Presentation of detailed data released at ESMO 2016 Congress, October 10, 2016. sNDA filing due 3Q 2017.
Cabozantinib - CABOSUN
First-Line RCC - cancer
Phase 3 initiated Sept 2013. Data due 2H 2017.
XL184 cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer